MAP1LC3A and Hepatic fibrosis: In line with these findings, we demonstrated that PG545 significantly decreased IL-6 and LC3 levels in liver homogenates, reflecting an additional favorable effect of heparanase inhibition towards preventing the development of liver fibrosis.